Immunovant insider exercises options, sells 1,500

Immunovant, Inc. (IMVT) director Atul Pande exercised fully vested stock options to acquire 1,500 shares of common stock at an exercise price of $8.43 per share and on the same date sold 1,500 shares at $43.27 per share.

Rhea-AI Filing Summary

Immunovant, Inc. (IMVT) director Atul Pande exercised fully vested stock options to acquire 1,500 shares of common stock at an exercise price of $8.43 per share and on the same date sold 1,500 shares at $43.27 per share. Following the option exercise, he holds 65,181 options directly, and a separate indirect holding shows 20,000 shares held by a trust. The reported transactions were effected pursuant to a Rule 10b5-1 Plan adopted on December 26, 2025.

Insider Trade Summary 10b5-1

Exercise and Sale: 1,500 shares ($52K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Pande Atul

Role Director

Sold 1,500 shs ($65K)

Approx. gross sale proceeds $65K

Approx. exercise cost $13K

Approx. pre-tax spread $52K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F1, F2	1,500	$0.00	$0.00
Exercise	Common Stock F1	1,500	$8.43	$13K
Sale	Common Stock F1	1,500	$43.27	$65K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 65,181 contracts (Direct); Common Stock — 116,731 shares (Direct); Common Stock — 20,000 shares (Indirect, By Trust)

Footnotes (2)

1. F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025.
2. F2. Reflects an award of stock options to purchase Common Shares that is fully vested.

Key Figures

Options Exercised: 1,500 shares Exercise Price: $8.43 per share Shares Sold: 1,500 shares +5 more

8 metrics

Options Exercised 1,500 shares Stock options to buy Immunovant, Inc. common stock exercised on August 28, 2026

Exercise Price $8.43 per share Exercise price of stock options exercised for 1,500 shares

Shares Sold 1,500 shares Common stock sold on August 28, 2026 in an open market or private transaction

Sale Price $43.27 per share Price per share received for the 1,500 Immunovant, Inc. shares sold

Options Held After Transaction 65,181 options Total stock options directly held following the reported option exercise

Indirect Shares Held by Trust 20,000 shares Common stock held indirectly by trust for the reporting person

Option Expiration Date November 19, 2029 Expiration date of the exercised stock option award

Rule 10b5-1 Plan Adoption Date December 26, 2025 Date the reporting person adopted the trading plan governing these transactions

Key Terms

Rule 10b5-1 Plan, Stock Option (right to buy), Exercise or conversion of derivative security, indirect, +1 more

5 terms

Rule 10b5-1 Plan regulatory

"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted..."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy) with an exercise price..."

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

indirect financial

"ownership_type: indirect, nature_of_ownership: By Trust"

By Trust financial

"nature_of_ownership: By Trust for 20,000 indirect shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Atul Pande report in this Form 4 for IMVT?

He reported exercising 1,500 stock options for Immunovant, Inc. common stock at an exercise price of $8.43 per share and selling 1,500 shares at $43.27 per share on August 28, 2026, under a Rule 10b5-1 Plan.

What is the exercise price of the options exercised in IMVT?

The exercised stock options had an exercise price of $8.43 per share, covering 1,500 shares of Immunovant, Inc. common stock, with the options fully vested and expiring on November 19, 2029.

At what price were IMVT shares sold in this Form 4?

The Form 4 reports a sale of 1,500 shares of Immunovant, Inc. common stock at a price of $43.27 per share on August 28, 2026, in an open market or private transaction.

How many IMVT options does Atul Pande hold after these transactions?

After the reported option exercise, Atul Pande holds 65,181 stock options directly in Immunovant, Inc., according to the post-transaction derivative holdings reported.

Does Atul Pande have any indirect holdings of IMVT shares?

Yes. The filing lists an indirect holding of 20,000 shares of Immunovant, Inc. common stock, held by trust, separate from his direct option and share positions.

Were the IMVT transactions made under a Rule 10b5-1 trading plan?

Yes. A footnote states the reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by Atul Pande on December 26, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 04:29 PM EDT Accepted by SEC EDGAR 08/28/2026 - 04:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pande Atul

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/28/2026		M(1)		1,500	A	$8.43	118,231	D
Common Stock	08/28/2026		S(1)		1,500	D	$43.27	116,731	D
Common Stock								20,000	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.43	08/28/2026		M(1)			1,500	(2)	11/19/2029	Common Stock	1,500	$0	65,181	D

Explanation of Responses:

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025.

2. Reflects an award of stock options to purchase Common Shares that is fully vested.

Remarks:

	/s/ Tiago Girao, attorney-in-fact for Atul Pande	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)